Yingchuan (Grace) Mo

Grace Mo represents public and private companies in mergers, acquisitions, dispositions, investments and securities offerings. She also advises companies on securities law compliance, shareholder activism and corporate governance matters.

Examples of Ms. Mo’s representations include:

• Anaplan, Inc., as co-counsel, in its $10.7 billion acquisition of Thoma Bravo;
• FaZe Clan Inc. in its $1 billion merger with B. Riley Principal 150 Merger Corp.;
• Reinvent Technology Partners in its:
  • $6.6 billion merger with Joby Aviation; and
  • $11 billion merger with Aurora Innovation, Inc;
• 8x8, Inc. in its:
  • $250 million acquisition of Fuze, Inc.; and
  • $137.5 million private placement of 0.5% convertible senior notes due 2024;
• Apartment Investment and Management Company in its $10.4 billion spin-off of Apartment Income REIT;
• Credit Karma in its:
  • $8.1 billion acquisition by Intuit; and
  • $50 billion divestiture of its tax business, Credit Karma Tax, to Square, Inc.;
• Danaher Corporation in the initial public offering and split-off of Envista Holdings Corporation;
• Fortive Corporation in a $3 billion reverse Morris trust transaction involving the merger of its automation and specialty business with Altra Industrial Motion Corp., and split-off exchange offer of shares of the combined business for shares of Fortive common stock;
• Envision Building Products in its acquisition of Fairway Architectural Railing Solutions;
• TAMKO Building Products in connection with an investment by The Carlyle Group;
• Altaba Inc. in various matters, including:
  • its plan of liquidation and dissolution;
  • its self-tender offer for up to 195 million shares of its common stock in exchange for cash and Alibaba Group Holding Limited American depositary shares; and
  • the sale, in two separate transactions, of its equity stake in Yahoo Japan Corporation for $6.3 billion;
• Eurazeo in the acquisition of Planet Payment, Inc. through Fintrax Group, its portfolio company; and
• BeyondSpring Inc., a clinical-state biopharmaceutical company, in its initial public offering.